February 13, 2019 COMPANY PRESENTATION – February 2019
Posted at 08:15h
in Uncategorized
Download presentation...
February 13, 2019 VACCIBODY ANNOUNCES COLLABORATION TO STUDY VB10.16 AND ATEZOLIZUMAB (TECENTRIQ®) IN ADVANCED CERVICAL CANCER
Posted at 08:15h
in Uncategorized
Vaccibody AS, a clinical stage immuno-oncology company, announced today that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Vaccibody expects to start a phase II...
February 13, 2019 VACCIBODY AS LAUNCHES A PRIVATE PLACEMENT OF NEW SHARES OF NOK 230 MILLION
Posted at 08:15h
in Uncategorized
Vaccibody AS ("Vaccibody" or the "Company"), a clinical stage immuno-oncology company, is contemplating to offer new shares (the "Offer Shares") in a private placement raising gross proceeds of approximately NOK 230 million (the "Private Placement"). The subscription price per Offer Share in the Private Placement...
November 9, 2018 QUARTERLY REPORT – 2018 Q3
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q3...
October 10, 2018 VACCIBODY UPDATES ON CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL: FIRST 10 PATIENTS ENROLLED, AND VACCINATIONS STARTED.
Posted at 12:00h
in Uncategorized
Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces that the first 10 patients have been enrolled in its phase I/IIa cancer neoantigen vaccine trial and that vaccinations with VB10.NEO have started. The trial...
September 26, 2018 Positive results from the 6-months Interim analysis of the phase IIa clinical study in high grade cervical dysplasia provides Proof-of-Concept for Vaccibody’s immunotherapy platform.
Posted at 10:00h
in Uncategorized
Vaccibody AS today announced positive 6-months interim results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...
September 20, 2018 Vaccibody announces clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibody’s personalized cancer neoantigen vaccine in combination with Nektar’s CD-122-biased agonist, NKTR-214
Posted at 10:00h
in Uncategorized
Vaccibody AS today announced a new clinical collaboration with Nektar Therapeutics to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s CD-122-biased agonist, NKTR-214. VB10.NEO is designed to specifically activate the patient’s immune system to tumour specific antigens, called neoantigens. NKTR-214 is designed to...
August 24, 2018 QUARTERLY REPORT – 2018 Q2
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q2...
July 11, 2018 Annual Report 2017
Posted at 10:15h
in Uncategorized
Vaccibody - Annual report 2017...
May 14, 2018 QUARTERLY REPORT – 2018 Q1
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q1...